Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Corash

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Transfusion|November 8, 2005
Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patientsRichard J Benjamin, Jeffrey McCullough, Paul D Mintz, et al.
Transfusion|November 29, 2025
Amustaline/glutathione pathogen-reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trialIan J Welsby, Michael E Sekela, Edward L Snyder, et al.
Transfusion|February 2, 2010
An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatmentJean-Pierre Cazenave, Chantal Waller, Daniel Kientz, et al.
Transfusion|October 2, 2019
Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 daysLaura Infanti, Andreas Holbro, Jakob Passweg, et al.
Transfusion|April 19, 2025
A novel acridine flow cytometry marker to track post-transfusion amustaline/glutathione pathogen-reduced red blood cell survival in sickle cell disease patientsRichard J Benjamin, John P Pitman, Christopher Karim, et al.
British Journal of Haematology|March 23, 2011
A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusionMiguel Lozano, Folke Knutson, René Tardivel, et al.
Transfusion|March 5, 2020
Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United StatesChristina L Dean, Jay W Hooper, John M Dye, et al.
Scientific Reports|April 7, 2021
Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarrayRafael Assis, Aarti Jain, Rie Nakajima, et al.
Transfusion|August 5, 2005
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficienciesPedro de Alarcon, Richard Benjamin, Marion Dugdale, et al.
Transfusion|March 29, 2019
Transfusion of pathogen-reduced platelet components without leukoreductionJoycelyn Sim, Wai Chiu Tsoi, Cheuk Kwong Lee, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Transfusion|November 8, 2005
Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patientsRichard J Benjamin, Jeffrey McCullough, Paul D Mintz, et al.
Transfusion|November 29, 2025
Amustaline/glutathione pathogen-reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trialIan J Welsby, Michael E Sekela, Edward L Snyder, et al.
Transfusion|February 2, 2010
An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatmentJean-Pierre Cazenave, Chantal Waller, Daniel Kientz, et al.
Transfusion|October 2, 2019
Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 daysLaura Infanti, Andreas Holbro, Jakob Passweg, et al.
Transfusion|April 19, 2025
A novel acridine flow cytometry marker to track post-transfusion amustaline/glutathione pathogen-reduced red blood cell survival in sickle cell disease patientsRichard J Benjamin, John P Pitman, Christopher Karim, et al.
British Journal of Haematology|March 23, 2011
A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusionMiguel Lozano, Folke Knutson, René Tardivel, et al.
Transfusion|March 5, 2020
Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United StatesChristina L Dean, Jay W Hooper, John M Dye, et al.
Scientific Reports|April 7, 2021
Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarrayRafael Assis, Aarti Jain, Rie Nakajima, et al.
Transfusion|August 5, 2005
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficienciesPedro de Alarcon, Richard Benjamin, Marion Dugdale, et al.
Transfusion|March 29, 2019
Transfusion of pathogen-reduced platelet components without leukoreductionJoycelyn Sim, Wai Chiu Tsoi, Cheuk Kwong Lee, et al.
Pageof 7